In vitro and in vivo anticancer action of saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells

Cell Cycle

Volumn 10, Issue 3, 2011, Pages 492-499

  Donia, Marco ^a   Maksimovic Ivanic, Danijela ^b   Mijatovic, Sanja ^b   Mojic, Marija ^b   Miljkovic, Djordje ^b   Timotijevic, Gordana ^c   Fagone, Paolo ^a   Caponnetto, Salvatore ^a   Al Abed, Yousef ^d   McCubrey, James A ^e   Stosic Grujicic, Stanislava ^b   Nicoletti, Ferdinando ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c Belgrade University   (Serbia)

^d East Carolina University ^*  (United States)

^e EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Apoptosis; Chemosenzitization; Immunosensitization; Nitric oxide modified saquinavir; Prostate cancer

Indexed keywords

BIM PROTEIN; DEATH RECEPTOR 5; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53; PROTEINASE INHIBITOR; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SAQUINAVIR NITRIC OXIDE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; CYTOSTASIS; HORMONE RESISTANCE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; TARGET CELL; TUMOR XENOGRAFT;

EID: 79851501503     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.3.14727     Document Type: Article

References (34)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18:581-92.
2. Cooperberg MR, Hinotsu S, Namiki M, Ito K, Broering J, Carroll PR, et al. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol 2009; 27:4306-13.
3. de Wit R. Chemotherapy in hormone-refractory prostate cancer. BJU Int 2008; 101:11-5.
4. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351:1513-20. (Pubitemid 39315318)
5. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26:242-5.
6. Lebbe C, Blum L, Pellet C, Blanchard G, Vérola O, Morel P, et al. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. AIDS 1998; 12:45-9.
7. Bower M, Fox P, Fife K, Gill J, Nelson M, Gazzard B. Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. AIDS 1999; 13:2105-11. (Pubitemid 29509588)
8. Chow WA, Jiang C, Guan M. Anti-HIV drugs for cancer therapeutics: Back to the future? Lancet Oncol 2009; 10:61-71.
9. Sgadari C, Barillari G, Toschi E, Carlei D, Bacigalupo I, Baccarini S, et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 2002; 8:225-32. (Pubitemid 34250099)
10. Pajonk F, Himmelsbach J, Riess K, Sommer A, McBride WH. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res 2002; 62:5230-5. (Pubitemid 35024595)
11. Gupta AK, Cerniglia GJ, Mick R, McKenna WG, Muschel RJ. HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Cancer Res 2005; 65:8256-65. (Pubitemid 41330590)
12. McLean K, VanDeVen NA, Sorenson DR, Daudi S, Liu JR. The HIV protease inhibitor saquinavir induces endoplasmic reticulum stress, autophagy and apoptosis in ovarian cancer cells. Gynecol Oncol 2009; 112:623-30.
13. Timeus F, Crescenzio N, Ricotti E, Doria A, Bertin D, Saglio G, et al. The effects of saquinavir on imatinib-resistant chronic myelogenous leukemia cell lines. Haematol 2006; 91:711-2. (Pubitemid 43799479)
14. Mijatovic S, Maksimovic-Ivanic D, Timotijevic G, Miljkovic D, Donia M, Libra M, et al. Induction of caspase-independent apoptotic-like cell death of mouse mammary tumor TA3Ha cells in vitro and reduction of their lethality in vivo by the novel chemotherapeutic agent GIT-27NO. Free Radic Biol Med 2010; 48:1090-9.
15. Donia M, Mijatovic S, Maksimovic-Ivanic D, Miljkovic D, Mangano K, Tumino S, et al. The novel NO-donating compound GIT-27NO inhibits in vivo growth of human prostate cancer cells and prevents murine immunoinflammatory hepatitis. Eur J Pharmacol 2009; 615:228-33.
16. Mijatovic S, Maksimovic-Ivanic D, Mojic M, Malaponte G, Libra M, Cardile V, et al. Novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5- isoxazole acetic acid-nitric oxide (GIT-27NO) induces p53 mediated apoptosis in human A375 melanoma cells. Nitric Oxide 2008; 19:177-83.
17. Maksimovic-Ivanic D, Mijatovic S, Harhaji L, Miljkovic D, Dabideen D, Fan Cheng K, et al. Anticancer properties of the novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide in vitro and in vivo. Mol Cancer Ther 2008; 7:510-20. (Pubitemid 351482134)
18. Rigas B, Williams JL. NO-donating NSAIDs and cancer: An overview with a note on whether NO is required for their action. Nitric Oxide 2008; 19:199-204.
19. Rigas B, Kashfi K. Nitric-oxide-donating NSAIDs as agents for cancer prevention. Trends Mol Med 2004; 10:324-30. (Pubitemid 38881521)
20. Maksimovic-Ivanic D, Mijatovic S, Miljkovic D, Harhaji-Trajkovic L, Timotijevic G, Mojic M, et al. The antitumor properties of a nontoxic, nitric oxide-modified version of saquinavir are independent of Akt. Mol Cancer Ther 2009; 8:1169-78
21. Siemens DR, Heaton JP, Adams MA, Kawakami J, Graham CH. Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer. Urology 2009; 74:878-83.
22. Rothweiler F, Michaelis M, Brauer P, Otte J, Weber K, Fehse B, et al. Anti-cancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multi-drug resistant cancer cells. Neoplasia 2010; 12:1023-30.
23. O'Connor L, Strasser A, O'Reilly LA, Hausmann G, Adams JM, Cory S, et al. Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J 1998; 17:384-95.
24. Bouillet P, Metcalf D, Huang DC, Tarlinton DM, Kay TW, Köntgen F, et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis and to preclude autoimmunity. Science 1999; 286:1735-8. (Pubitemid 129515880)
25. L/Bim fragment complex: implications for Bim function. Immunity 2003; 19:341-52.
26. Al-Katib AM, Sun Y, Goustin AS, Azmi AS, Chen B, Aboukameel A, et al. SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status. J Hematol Oncol 2009; 2:8.
27. Van Ophoven A, Ng CP, Patel B, Bonavida B, Belldegrun A. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) for treatment of prostate cancer: first results and review of the literature. Prostate Cancer Prostatic Dis 1999; 2:227-33. (Pubitemid 30252199)
28. Wu GS. TRAIL as a target in anti-cancer therapy. Cancer Lett 2009; 285:1-5.
29. Shetty S, Graham BA, Brown JG, Hu X, Vegh-Yarema N, Harding G, et al. Transcription factor NFkappaB differentially regulates death receptor 5 expression involving histone deacetylase 1. Mol Cell Biol 2005; 25:5404-16. (Pubitemid 40853578)
30. Gomes NP, Espinosa JM. Differential regulation of p53 target genes: It's (core promoter) elementary. Genes Dev 2010; 24:111-4.
31. Fan Y, Dutta J, Gupta N, Fan G, Gélinas C. Regulation of programmed cell death by NFkappaB and its role in tumorigenesis and therapy. Adv Exp Med Biol 2008; 615:223-50.
32. Wang H, Hertlein E, Bakkar N, Sun H, Acharyya S, Wang J, et al. NFkappaB regulation of YY1 inhibits skeletal myogenesis through transcriptional silencing of myofibrillar genes. Mol Cell Biol 2007; 27:4374-87. (Pubitemid 46906562)
33. Nozaki S, Sledge GW Jr, Nakshatri H. Repression of GADD153/CHOP by NFkappaB: A possible cellular defence against endoplasmic reticulum stress-induced cell death. Oncogene 2001; 20:2178-85. (Pubitemid 32424012)
34. Huerta-Yepez S, Vega M, Escoto-Chavez SE, Murdock B, Sakai T, Baritaki S, et al. Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1. Nitric Oxide 2009; 20:39-52.